What Is IGF-1 LR3 and What Muscle Research Now Shows

IGF-1 LR3 is a lab-made version of IGF-1, a growth-related hormone your body makes naturally. It is sold online to people who want to build muscle, and that is why so many people search for it. But it has never been approved for use in people, and no human trial has tested it for muscle growth. This guide explains what IGF-1 LR3 is, what lab studies of muscle report, why there is no proven dose or cycle length, and what side effects the research record points to. It describes research only and is not advice for any person.

What Is IGF-1 LR3?

IGF-1 stands for insulin-like growth factor 1. It is a hormone that looks a little like insulin. Your liver makes most of it after growth hormone (GH) gives the signal. IGF-1 then travels through the blood and tells muscle, bone, cartilage, and other tissues to grow and repair. Its levels are highest during the teenage growth spurt and fall slowly with age.

In muscle, a 2020 review in the journal Cells explains that IGF-1 switches on a chain of signals inside the cell (called PI3K, Akt, and mTOR). Those signals raise the cell’s output of new muscle protein and slow down protein breakdown. IGF-1 also wakes up muscle stem cells, called satellite cells, which help muscle repair itself.

IGF-1 LR3 is IGF-1 with two changes. The “R3” means one building block at position 3 was swapped for another one, called arginine. The “Long” means a short extra stretch of amino acids was added to the front end. A 1996 paper in the journal Growth Factors describes this “N-terminal extended” design.

Why make those changes? Most IGF-1 in the blood is held by six carrier proteins called IGF binding proteins. A 2018 review in the Journal of Molecular Endocrinology explains that these proteins act like a storage and control system. They carry IGF-1 around, and they can hold it back or release it. IGF-1 LR3 binds those carriers poorly, so more of it stays free to act. Lab studies describe it as the more potent form, and a 2017 paper notes that it has been described as lasting longer in the body than natural IGF-1.

Where does it sit next to the other growth compounds on this site? Compounds like CJC-1295 and ipamorelin and the oral compound covered in the MK-677 research guide are called secretagogues. They are studied for prompting the pituitary gland to release GH, and IGF-1 rises afterward as a result. IGF-1 LR3 skips that step. It is a copy of the downstream hormone itself.

Feature	Natural IGF-1	IGF-1 LR3	Secretagogues
What it is	Hormone your liver makes	Lab-made modified copy	Compounds that prompt GH release
Where it acts	Downstream, on tissues	Downstream, on tissues	Upstream, at the pituitary
Binding proteins	Held by six carriers	Binds carriers poorly	Not applicable
Human research	Approved medicine for rare cases	None found	Varies by compound

What Is the Optimal IGF-1 LR3 Dosage for Muscle Growth?

There is no optimal dose, because no dose has been tested for muscle growth in people. A 2026 review in Frontiers in Endocrinology looked at compounds like this one that are sold as “research compounds.” It sorted them by how strong their evidence is, from large regulated trials down to a complete absence of human studies. It contrasts that evidence with the self-administration plans shared online, and it points to uncertainty about product contents and doses in unregulated supply.

You will find exact numbers on shop pages, forums, and supplement sites. This guide does not repeat them. They are not from clinical trials, they vary a great deal from site to site, and there is no evidence behind them.

The research record does support a few points.

Lab doses are not human doses. Lab studies set amounts for their own experiments, and those amounts cannot be turned into an amount for a person.
The approved IGF-1 is a different product. A related medicine, mecasermin, is natural-sequence IGF-1. It is used under medical care for children with a rare condition of severe IGF-1 shortage. Its dosing says nothing about IGF-1 LR3.
More potent can mean harder to predict. Because IGF-1 LR3 is not held back by its carrier proteins, it behaves differently from natural IGF-1, so lessons from one do not simply carry over to the other.

What Are the Side Effects of IGF-1 LR3?

No safety study in people exists for IGF-1 LR3. What follows are signals from the wider literature on IGF-1 and its look-alikes. They are warnings that researchers raise, not a list of what will happen.

Low blood sugar. IGF-1 acts a bit like insulin. A 2009 review in Advances in Therapy says low blood sugar is the most frequent side effect of mecasermin. A European registry of 306 children treated with it found that 80 of them, about one in four, had at least one low blood sugar event. That registry, published in 2023, covered children treated under medical care. The 2009 review also notes that concern about eye damage (retinopathy) has held back trials of IGF-1 for diabetes.
Hormone and fluid changes. The 2026 Frontiers review lists reported problems across this group of compounds, including blood sugar swings, higher prolactin and cortisol, fluid retention, muscle and joint aches, and injection-site reactions.
Effects on the body’s own hormones. In a 1997 lab growth study, IGF-1 LR3 lowered the body’s own GH and IGF-1 instead of raising them, and growth measures fell. This is the opposite of what sellers imply.
Uneven tissue growth. A 1995 lab study found that after a week of IGF-1 LR3, the gut, kidneys, spleen, and adrenal glands grew in relative size, but overall body growth did not rise. A 2014 review of muscle therapy research says a key challenge is driving growth in muscle without driving unwanted growth in other tissues.
Cancer questions. A 2016 pooled analysis of over 10,000 prostate cancer cases found that men in the top fifth for natural IGF-1 blood levels had about 29 percent higher odds of prostate cancer than men in the bottom fifth. A 2017 review explains that IGF-1 signaling pushes cells to multiply and blocks cell death, which is why it is studied in cancer. These findings are about natural levels, not about IGF-1 LR3. But they explain why researchers are cautious about a more potent version.
Unknown contents. A 2010 case report found that an injection vial sold on the illegal market held a lab by-product called His-tagged Long-R3-IGF-I, with effects in humans unknown. A 2021 detection study found signs of lower-quality, oxidized forms in illegal-market products.

How Many Weeks Should an IGF-1 Cycle Last?

There is no research-based answer. “Cycle” is a term from bodybuilding forums, and it does not come from clinical research. No study has tested a cycle length, a break length, or a schedule of any kind for IGF-1 LR3 in people.

The lab studies used short windows, such as 4 to 7 days of continuous infusion, chosen for the experiment. They cannot be stretched into a weeks-long plan for a person.

Two research findings matter here. The 1997 lab study showed that IGF-1 LR3 can suppress the body’s own GH signal, so the body responds to it. Nobody has measured what happens to that response over weeks in people. Separately, anti-doping researchers report that IGF-1 LR3 breaks down quickly in lab samples. A 2021 study found the intact molecule disappeared within about 4 hours, while a breakdown product could be seen for up to 16 hours. These findings are about detection, not about how long any effect lasts.

IGF-1 and its look-alikes, including LR3, are on the World Anti-Doping Agency’s prohibited list, according to a 2017 paper in Growth Hormone and IGF Research.

IGF-1 LR3 Before and After, What the Research Shows

You will not find reliable before and after results here, because no human study has measured them. Photos and stories online are not research, and the products behind them often are not what the label says.

What the research does show is mixed.

Cell studies. In cultured muscle cells, a 2004 study in the Journal of Cellular Physiology reported that IGF-1 LR3 drove cells to multiply even when a binding protein was present. A 2005 study in the Journal of Endocrinology found similar results. But a 2001 study found that in some muscle cell types, the LR3 form was less active than natural IGF-1, and it linked this to weaker binding to the growth receptor. The change that helps it avoid carriers may also change how well it binds the receptor.
Whole-body lab studies. The 1995 study found organ growth but no change in overall growth or body makeup. The 1997 study found lower growth and lower natural GH and IGF-1. A 2002 study found that IGF-1 LR3 raised gut tissue mass more than it improved how well the gut absorbed sugar.
Muscle in general. The 2014 review says IGF-1 has long been seen as a key factor in muscle growth, repair, mass, and strength. It also says better tools are needed to point that growth at muscle. That is a statement about IGF-1 in general, not a finding for IGF-1 LR3.

The honest summary is that IGF-1 clearly matters for muscle in lab work. But whether IGF-1 LR3 builds muscle in people is unknown.

IGF-1 LR3 Dosage and Lab Handling

There is no tested dose of IGF-1 LR3 for people, and this guide does not give one.

For researchers who handle the material in a lab, three practical points apply.

Check what you have. Given the cases of mislabeled and degraded product above, the supplier’s Certificate of Analysis, which lists identity and purity, is the first thing to read.
Follow the supplier’s handling sheet. Freeze-dried proteins are generally kept cold and protected from light. Exact storage and mixing steps depend on the product, so use the supplier’s sheet instead of general rules.
Use the general guide for mixing basics. The peptide reconstitution guide explains the common steps for freeze-dried research material.

HORMONE THERAPY

Ipamorelin

Shop Now

Frequently Asked Questions

Is IGF-1 LR3 the same as growth hormone?

No. Growth hormone is made in the pituitary gland and tells the liver to make IGF-1. IGF-1 LR3 is a lab-made copy of the second hormone in that chain.

How is IGF-1 LR3 different from regular IGF-1?

It has one swapped building block and an extra stretch added to the front end. These changes make it bind carrier proteins poorly, so more of it stays free in lab studies.

Is IGF-1 LR3 approved for people?

No. A 2021 paper states that IGF-1 LR3 and related analogs were never approved for use in humans. The main approved IGF-1 medicine is mecasermin, which has the natural sequence and is used for a rare growth condition in children.

Has IGF-1 LR3 been shown to build muscle in people?

No human trial has been found. Muscle findings come from cell cultures and lab models, and they are mixed, as the before and after section above explains.

How is IGF-1 LR3 different from CJC-1295 and ipamorelin?

Those two prompt the body to release more GH, and IGF-1 rises afterward. IGF-1 LR3 is the downstream hormone copy. See the ipamorelin vs sermorelin comparison and the tesamorelin guide for more on that group.

Does IGF-1 LR3 show up in drug tests?

Anti-doping labs have built methods to detect it using blood samples and mass spectrometry. Several papers describe the work, and a 2021 paper says the molecule clears quickly.

Key Takeaways

IGF-1 LR3 is a lab-made version of IGF-1, built to bind carrier proteins poorly. It is not a secretagogue, because it is the downstream hormone copy and not a signal to release GH.
No human trial has tested IGF-1 LR3 for muscle growth. It has never been approved for use in humans.
There is no optimal dose and no research-based cycle length. Exact numbers online do not come from clinical trials.
The side effect concerns raised in the literature include low blood sugar, hormone and fluid changes, uneven tissue growth, cancer questions, and unreliable product contents.
Lab results on muscle are mixed. Cell studies show growth signals, and whole-body lab studies show organ growth or lower growth, not clear muscle gain.
It is on the World Anti-Doping Agency’s prohibited list with IGF-1 and its look-alikes.

Research Use Disclaimer

This content is provided for Research Use Only (RUO). The compounds discussed are not drugs, dietary supplements, foods, or cosmetics, and are not intended for human or animal consumption, diagnostic use, or therapeutic use of any kind. They have not been evaluated by the FDA for safety or efficacy in humans. Any research use must be conducted by qualified professionals in a controlled laboratory environment, in accordance with all applicable institutional, local, and federal regulations.

Sources

Wikipedia contributors. Insulin-like growth factor 1. Wikipedia, The Free Encyclopedia.
Yoshida T, Delafontaine P. Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cells. 2020.
Philippou A, et al. Optimizing IGF-I for skeletal muscle therapeutics. Growth Horm IGF Res. 2014.
Bach LA. IGF-binding proteins. J Mol Endocrinol. 2018.
Bryant KJ, et al. Design and characterisation of long-R3-insulin-like growth factor-I muteins which show resistance to pepsin digestion. Growth Factors. 1996.
Conlon MA, et al. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations. J Endocrinol. 1995.
Dunaiski V, et al. Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations. J Endocrinol. 1997.
Xi G, et al. Effect of recombinant porcine IGFBP-3 on IGF-I and long-R3-IGF-I-stimulated proliferation and differentiation of L6 myogenic cells. J Cell Physiol. 2004.
Pampusch MS, et al. Production of recombinant porcine IGF-binding protein-5 and its effect on proliferation of embryonic myoblast cultures in the presence and absence of IGF-I and Long-R3-IGF-I. J Endocrinol. 2005.
Pesall JE, et al. The effect of insulin-like growth factor analogs on satellite cell and embryonic myoblast proliferation. Poult Sci. 2001.
Garnaut SM, et al. Effects of insulin-like growth factor-I and its analogue, long-R3-IGF-I, on intestinal absorption of 3-O-methyl-D-glucose are less pronounced than gut mucosal growth responses. Growth Factors. 2002.
Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol. 2026.
Rosenbloom AL. Mecasermin (recombinant human insulin-like growth factor I). Adv Ther. 2009.
Bang P, et al. Frequency and predictive factors of hypoglycemia in patients treated with rhIGF-1, data from the Eu-IGFD Registry. J Clin Endocrinol Metab. 2023.
Travis RC, et al. A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk. Cancer Res. 2016.
Kasprzak A, et al. Insulin-like growth factor (IGF) axis in cancerogenesis. Mutat Res Rev Mutat Res. 2017.
Kohler M, et al. Detection of His-tagged Long-R3-IGF-I in a black market product. Growth Horm IGF Res. 2010.
Mongongu C, et al. Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes. Drug Test Anal. 2021.
Thomas A, et al. Determination of LongR3-IGF-I, R3-IGF-I, Des1-3 IGF-I and their metabolites in human plasma samples by means of LC-MS. Growth Horm IGF Res. 2017.

Explore the hormone therapy research category for related compounds, or view the Ipamorelin research material and the full shop.